Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer
NCT01010854
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
6
Enrollment
OTHER
Sponsor class
Stopped
Premature closure for lack of efficacy.
Conditions
Breast Cancer
Interventions
DRUG:
VPA FEC100
Sponsor
University of California, San Francisco
Collaborators
[object Object]